Problem: Delayed labour progress is common in nulliparous women, often leading to caesarean section despite augmentation of labour with synthetic oxytocin. Background: High-or low-dose oxytocin can be used for augmentation of delayed labour, but evidence for promoting high-dose is weak. Aim To ascertain the effect on caesarean section rate of high-dose versus low-dose oxytocin for augmentation of delayed labour in nulliparous women. Methods Multicentre parallel double-blind randomised controlled trial (ClinicalTrials.gov: NCT01587625) in six labour wards in Sweden. Healthy nulliparous women at term with singleton cephalic fetal presentation, spontaneous labour onset, confirmed delay in labour and ruptured membranes (n = 1351) were randomised to labour augmentation with either high-dose (6.6 mU/minute) or low-dose (3.3 mU/minute) oxytocin infusion. Findings: 1295 women were included in intention-to-treat analysis (high-dose n = 647; low-dose n = 648). Caesarean section rates did not differ between groups (12.4% and 12.3%, 95% Confidence Interval À3.7 to 3.8). Women with high-dose oxytocin had: shorter labours (À23.4 min); more uterine tachysystole (43.2% versus 33.5%); similar rates of instrumental vaginal births, with more due to fetal distress (43.8% versus 22.7%) and fewer due to failure to progress (39.6% versus 58.8%). There were no differences in neonatal outcomes. Discussion: Our study could not confirm results of two systematic reviews indicating, with weak evidence, that use of high-dose oxytocin was associated with lower frequency of caesarean section. Conclusion: We found no advantages for routine use of high-dose oxytocin in the management of delay in labour. Low-dose oxytocin regimen is recommended to avoid unnecessary events of tachysystole and fetal distress. 
Introduction
Delayed labour progress is common in nulliparous women, and is among the leading indications for emergency caesarean section (CS). [1] [2] [3] [4] Synthetic oxytocin is one of the most frequently used medications in obstetric care 5 and the common routine for augmentation of labour. However, the effectiveness of oxytocin for treating abnormal progress has been questioned. 3, 6, 7 Despite that, over time an increased use of oxytocin during labour has been noted. An unstructured manner of using the drug prevails, 8, 9 and its use can lead to hyperactive uterine contractions, which have been associated with negative effects on the fetus. [10] [11] [12] Therefore, oxytocin has been designated as a high-alert medication. 13 Checklists and standardised protocols for the use of oxytocin have been recommended with the aim of reducing adverse neonatal outcomes. 14, 15 A meta-analysis of 8 trials comparing high and low dose oxytocin for induction of labour found no difference in CS rates, although more "uterine hyperstimulation" was noted in the high dose group. 16 Knowledge and consensus are lacking, however, regarding the proper dosage when oxytocin is used for accelerating slow progress of labour. 17 Women's experience of childbirth and pain in relation to oxytocin dosage is also insufficiently studied. Systematic reviews on the dosage of oxytocin 17, 18 have found that a high-dose (4-10 mU/min) compared to low-dose (1-4 mU/min) oxytocin regimen for treating delayed labour progress may reduce the risk of CS by 15%, 18 or by as much as 46%, 17 without any negative maternal or neonatal outcomes. However, the evidence for prioritising high-dose oxytocin is weak, and the Cochrane review on this topic (based on only four trials) recommended further research. 17 The need for further investigations has been highlighted, especially on neonatal outcomes and on women's childbirth experiences in relation to oxytocin dosage. 18, 17 More randomised controlled trials (RCTs) are justified to determine the effect of oxytocin augmentation on the likelihood of CS and other outcomes including women's satisfaction with care, which has been emphasised by the British Maternal and Foetal Medicine Society. 19 The overall aim of the study was to ascertain the effect on caesarean section rate of high-dose versus low-dose oxytocin for augmentation of delayed labour in nulliparous women. The hypothesis, based on weak evidence form a previous Cochrane review, 17 was that a high-dose oxytocin regimen, compared to a low-dose, will reduce the number of CSs without negative maternal and neonatal outcomes.
Methods

Study design and setting
A parallel double-blind, multicentre, randomised controlled trial (RCT) was conducted in accordance with the CONSORT guidelines 20 in four maternity units in Sweden including six labour wards: (removed for anonymity). The wards entered the study at different time points between September 2013 and June 2016. Data collection was completed in October 2016. Supplementary data on the participating labour wards are shown in Table S1 .
Participants
Eligible for inclusion were healthy, 21 nulliparous women with normal singleton pregnancies at term (37 + 0 to 41 + 6 gestational weeks), cephalic presentation, spontaneous onset of labour, active phase of labour (regular painful contractions and effaced cervix and dilation !3-4 cm), confirmed delayed labour progress, and ruptured membranes. Exclusion criteria were: age < 18 years, non-Swedish speaking, previous uterine surgery, clinically significant vaginal bleeding during labour, delayed labour progress with fetal head station below the ischial spines in second stage, suspected disproportion between fetal head and maternal pelvis, abnormal vertex presentation, suspected fetal growth restriction (<À2 standard deviations [SD]), 22 abnormal fetal heart rate (FHR) (suspicious or pathological cardotocograph), heavy meconium stained amniotic fluid, uterine tachysystole (defined as >5 contractions during 10 min for >20 min), maternal fever, and known hypersensitivity to oxytocin therapy. If any eligible women were already receiving oxytocin they were not included in the study, and women could be admitted to the study when delayed progress was identified at any stage of dilation (greater than 3-4 cm), or even in the second stage.
Randomisation and procedure
The study was conducted according to the study protocol with two exceptions: women were asked to participate when delayed labour was confirmed instead of being asked to participate at admission and, there was a change to a computer-generated randomisation system instead of using sealed envelopes.
Delayed labour was defined in accordance with the Swedish National recommendations, 23 by using a three-hour partogram action line for delay during the first stage of labour or an arrest of the descent of the fetal head for one to two hours during the second stage of labour. If a delayed labour was diagnosed together with intact membranes, amniotomy was performed. One hour later, an assessment was performed and, if there was no further progress, augmentation with oxytocin infusion was indicated. The woman received written and oral information about the study from the midwife. Consenting women were randomly allocated to receive a regimen of either a high-dose or a low-dose of oxytocin (33.2 or 16.6 mg oxytocin in 1000 ml isotonic saline solution), respectively).
These doses were chosen based on the definitions for low and high dose included in the latest Cochrane review on this topic. 17 Randomisation was generated by an external information technology-consultant using a computer-generated randomisation sequence, with allocation 1:1 ratio. There was no stratification by maternity unit. Randomisation and preparation of the oxytocin infusion according to the allocated dosage were handled by external staff, not working at the labour ward. Allocation was blinded for responsible staff, the woman in labour and for the research team. The random codes were revealed after completion of data collection and after the data file was closed.
In the high-dose group, the infusion started with 6.6 mU oxytocin/min (20 ml/h), and could be increased every 20 min by 6.6 mU to a maximum dose of 59.4 mU/min. In the low-dose group the infusion started with 3.3 mU oxytocin/min (20 ml/h), and could be increased every 20 min by 3.3 mU to a maximum dose of 29.7 mU oxytocin/min. The recommended standard dose in Sweden for oxytocin augmentation corresponds to the low-dose regimen in this study. 23 When more than 1000 ml of infusion with oxytocin was needed, the next oxytocin infusion, which was given to women in both groups, was the recommended standard dose (3.3 mU oxytocin/min) as clinicians would not know which strength had been given the first time. This was required for only 32 women (10 in high dose group and 22 in low dose group), 2.5% of the total and 1.5% of the high dose group.
In both groups the infusion was increased until adequate uterine contractions were obtained, and progress of labour was established (i.e. dilation of cervix and descent of the fetal head), or occurrence of a maximum of five contractions in 10 min. The monitoring and documentation of labour progress included assessment of maternal and fetal status and followed the study protocol and established routines based on national and departmental guidelines. In a checklist protocol, frequency of contractions every 10 min and electronic FHR pattern (normal/suspicious/pathological cardiotocography 24 [CTG]) were assessed and documented at every change of infusion rate, and once per hour after a therapeutic dose was obtained. Maternal blood pressure (at start of oxytocin infusion and once per hour for an oxytocin rate ! 180 ml/h) was registered. Adverse events (AEs) categorised as mild, moderate or severe were documented and evaluated.
Ethical issues
The study was approved by (removed), and by (removed). All women gave informed, written consent to take part. An independent Data and Safety Monitoring Board (DSMB) secured the project management through periodical reviews and an interim analysis of study specific data. A security team was established for the assessment of serious adverse events (SAEs). At each maternity unit there was a local principal investigator and a local research midwife responsible in charge for continuous supervision of security and labour management.
Data collection
Characteristics of study participants, and obstetric and neonatal data, were collected from the electronic medical record at each hospital (Obstetrix 1 or Cosmic 1 ). Data from the checklist protocol were reported in a shared internet database by the local research midwife. Delayed labour progress defined by the midwife or the obstetrician in charge of each woman was verified retrospectively by the local research midwives. All manually entered data were double-checked. The primary outcome was the rate of CS in labour. Secondary maternal outcomes were: instrumental vaginal birth, spontaneous vaginal birth, main indication for CS and instrumental vaginal birth (fetal distress, failure to progress or other indications), duration of labour (min), postpartum haemorrhage (>500 ml; >1000 ml), manual removal of placenta, anal sphincter injury (grade 3 or 4), fever during labour (>38.0 grade for two occasions after antipyretic medication), uterine tachysystole, total dose of oxytocin (mg), maximum oxytocin dose per minute (mg/min), total duration of oxytocin infusion (hour), oxytocin stopped or reduced temporarily, oxytocin stopped or reduced temporarily due to tachysystole together with suspicious or pathological FHR pattern. Neonatal outcomes included: Apgar score at 5 min <4 or <7; metabolic acidosis (umbilical cord arterial pH < 7.05 and base excess !À12 or umbilical cord arterial pH < 7.0), fetal distress (pathological CTG), intrapartum thick meconium stained amniotic fluid, admission to neonatal intensive care unit (NICU) and number of days stayed at NICU. Women's total experience of labour pain and their childbirth experience using the Childbirth Experience Questionnaire 25 will be reported later.
Analysis
The sample size was based on an assumed decrease of the CS rate from 17.5% to 13% i.e. a reduction of 25%. This required a total sample size of 2090 woman for 80% power at a significance level of p < 0.05. The rate of 17.5% was based on an earlier study of the same target group i.e. CS rate among nulliparous women with delayed labour 9 . A reduction of 25% was regarded as a clinically relevant reduction.
The independent DSMB reviewed the data periodically, using a group sequential method based on Haybittle-Peto rule to control for benefits and harms and need for early stopping of the trial. 26 After the sixth planned safety review, DSMB recommended termination of the trial for futility. 27 That interim analysis, which included 72 primary endpoint events (including CS) in the highdose group and 66 in the low-dose group (44% of those projected), demonstrated a less than 5% conditional power to demonstrate superiority to a p value < 0.05 if the trial were carried to completion. The Executive Steering Committee and sponsor accepted this recommendation, and the trial was terminated on June 8, 2016 . By completion of follow-up of all included women, and finalisation of the trial database on March 20, 2017, a total of 160 primary endpoint events (51% of those projected) were available for analysis. Statistical analyses were performed using SPSS 24.0 for Windows (SPSS Inc., Chicago, IL, USA) and SAS 9.4 (SAS Institute Inc., Cary, NC, USA). Primary and secondary outcome data were analysed on intention to treat (ITT) population and on per protocol (PP) population. Categorical variables are presented with n (%) and continuous variables with mean, standard deviation (SD), median, first quartile (q1) and third quartile (q3). For the comparison between two groups Fisher's Exact test was used for dichotomous variables, Chi-square test was used for non-ordered categorical variables and the Mann-Whitney U-test was used for continuous variables. Calculation of difference between groups for confidence interval (CI) in continuous variables was based on bootstrapping.
For exploratory purposes, an interaction analysis was performed for relevant baseline variables and dose group in relation to the primary outcome variable CS rate. If interactions were significant (p < 0.05), subgroup analyses were performed.
Results
On May 30, 2016 the DSMB recommended the Steering Committee to stop the study because of futility as there was no statistically significant difference in CS between the high-dose or low-dose group. The numeric difference between the two study groups was extremely small and the interim results suggested that it was unlikely to achieve statistical significance with a completed study.
During the study period, 5141 women were assessed for eligibility. A total of 1351 out of 2273 women who were eligible (59.4%) were randomised and 1295 were analysed on an intention to treat (ITT) basis, 647 in the high-dose and 648 in the low-dose group. Recruitment and flow are shown in Fig. 1 .
In total 56 women were excluded in the ITT analysis. Of these, 26 women were incorrectly included (induction of labour, gestational age < 37 weeks and !42 + 0, hepatitis, <18 years of age and breech presentation); 27 women had been immediately excluded after randomisation by the responsible midwife when detecting incorrectly inclusion and the woman was therefore deleted from the study. and three women withdrew consent after having been randomisation. Detailed information is given in Table S2 .2.
Included in the ITT analysis were 58 women incorrectly randomized according to inclusion/exclusion criteria: These women had either fever during labour, pathological or suspicious pathological CTG, fetal head station below the ichial spinae, thick meconium stained amniotic fluid, amniotomy after oxytocin infusion, adominal pain or myoma. Furthermor 38 women without delayed labour progress and 69 women who did not receive the allocated intervention were also included in the ITT analysis. Detailed information is given in Table S2 .1.
The baseline characteristics were similar in the two groups (Table 1) . There was no difference between the high-dose and the low-dose group with respect to the frequency of CS, 80 of 647 women (12.4%) versus 80 of 648 women (12.3%) (difference between groups 0.0, 95% CI À3.7 to 3.8) ( Table 2 ). CS rate in the different participating labour wards is shown in Table S4 . Table 1 Baseline characteristics of study groups. Secondary maternal and neonatal outcomes are presented in Tables 2 and 3 . The main indication for CS was failure to progress in both high-dose (55.0%) and low-dose groups (62.5%), but the difference was not significant (difference À7.5%, 95% CI À24.0 to 9.0). There were no significant differences in the rate of operative vaginal birth or spontaneous vaginal birth between the two regimens. The main indication for operative vaginal birth was fetal distress in the high-dose group (43.8% versus 22.7%, difference 21.1%, 95% CI 7.1 to 35.1) and failure to progress in the low-dose group (39.6% versus 58.8%, difference À19.2, 95% CI (-34.1 to À4.3).
Labour duration was 23 min shorter with a high-dose regimen of oxytocin (mean difference À23.4 min, 95% CI À45.1 to À1.5). No statistically significant differences were observed in the neonatal outcomes. In the low-dose group one perinatal death occurred in a child with severe hypoxic encephalopathy. It was regarded as not being related to the study drug.
The total dose of oxytocin used was significantly higher in the Table 3 ). There were more women with uterine tachysystole in the high-dose group (43.2% versus 33.5%; difference 9.6%; 95% CI 4.2 to 15.1). The rate of women in whom oxytocin was stopped or reduced temporarily due to uterine tachysystole together with suspicious or pathological FHR pattern was 21.1% in the high-dose group compared with 15.9% in the lowdose group (difference 5.1%, 95% CI 0.8 to 9.5). The proportion of women experiencing any adverse events did not differ significantly between the high-dose group and the lowdose group, 31/647 (4.8%) and 39/648 (6.0%), respectively (P = 0.39). Three women in the high-dose group and one in the low-dose group experienced a serious adverse event (SAE) (P = 0.37). None of the SAEs were regarded as drug-related. One woman with a SAE in the high-dose group did not receive treatment.
Per protocol analysis
In the per protocol analysis 1130 of 1295 women in ITT analysis were included, 96 incorrectly randomised women and 69 women who did not receive the allocated intervention were excluded. (Tables S2.1 + S2.2). The CS rate was 69/562 (12.3%) in the highdose group and 67/568 (11.8%) in the low-dose group (P = 0.87). The results were comparable with the results in ITT analyses (Table S3 ).
Interaction analyses and subgroup analyses
The analyses show a significant interaction between the latent phase and the randomised groups (P = 0.028). No interaction effects could be seen among the other baseline characteristics, for example maternal age (P = 0.052), stage of labour (first and second) (p = 0.49) and BMI (p = 0.32). In women with a prolonged latent phase (>18 h), the rate of CS was 7.7% in the high dose group compared with CS 11.9% in the low dose group (P = 0.20). In women with latent phase 18 h the CS rate was 14.9% in the high dose group compared to 12.8% in the low dose group (p = 0.48).
Discussion
Main finding
In this randomised controlled clinical trial there was no difference in CS rate between the high-oxytocin and low-oxytocin dose regimens for the treatment of delayed labour. A subgroup analysis investigating treatment with oxytocin in delayed labour in either first or second stage did not change these findings. Women in the high-dose group received a larger total amount of oxytocin and had a shorter duration of labour (by 23 min) and more events of tachysystole. They had similar rates of instrumental vaginal birth as women in the low-dose group, with more due to fetal distress (43.8% versus 22.7%) and fewer due to failure to progress (39.6% versus 58.8%), without any impact on the CS rate or on other maternal and neonatal outcomes.
Strengths and limitations
This study has several strengths. The use of oxytocin for augmentation has become routine in obstetric care, with few recent studies evaluating its effect on labour outcomes. Effects of early or delayed oxytocin augmentation on obstetric and neonatal outcomes have been investigated, 6, 28, 29 but recent RCTs evaluating oxytocin dosage for augmentation are missing. Our trial fills this gap. The double-blind RCT design reduced the risk for biases and skewed distribution of confounders. The comparison groups were well balanced. We had a common labour management protocol and the same oxytocin regimens among the different participating hospitals, which facilitated the analysis and interpretation of data. Delayed labour diagnosis was checked retrospectively by a small group of trained study midwives to avoid misclassification and to ensure consistency in assessments. All manually entered data were double-checked by team members, who also filled in missing data. This was time-consuming, but ensured the quality of the data. The external validity of the study was strengthened by the multicentre approach and the fact that the trial was conducted in different regions of Sweden, which increased the opportunity to generalise. A limitation, which might be a threat to the external validity was that we excluded 56 women (4%) from the ITT analysis due to not fulfilling inclusion criteria (for instance induction of labour, pre-or post-term labour, breech presentation or incorrect randomisation detected immediately after randomisation and without intervention). The midwife or obstetrician responsible for the care of the women had no contact with the randomisation procedure when the decision not to include the woman in the study was made directly after randomisation.
One weakness of our study is the number of women randomised but not fulfilling inclusion or exclusion criteria, which also could create a problem for the validity of the study. In order not to endanger the validity, both ITT analysis and analysis "per protocol" were performed, with similar results. Another limitation is that the study was stopped early for futility. An interim analysis found that it was unlikely to reach a significant difference in CS rate with the original target sample size of 2090 women. Women in the low-dose group had a lower CS rate than assumed in our sample size calculation, which may be explained by the strict inclusion and exclusion criteria i.e our result showing a CS rate of 12.4% (high-dose group) versus 12.3% (low-dose group) could reflect a study population of healthy nulliparous women, in the active phase of spontaneous labour (regular painful contractions and effaced cervix and dilation !3-4 cm), and with a healthy fetus on entering the study. An earlier Swedish RCT by Dencker et al 7 , comparing early and expectant oxytocin showed a similar low CS rate in the same kind of a population (9.2% versus 10.8%). In addition the Swedish rates of CS have not increased as much as in other western countries and is lower (17.6% in 2016) than in other countries.
A limitation could be the decision to change the protocol by approaching women to participate when their labour has been Calculation of confidence interval for continuous variables is based on bootstrapping of 10,000 replicates picking the 2.5 and 97.5 percentiles of the 10,000 mean differences as confidence interval (CI). a Definition of tachysystole: "more than five uterine contractions in 10 min for longer than 20 min". 17 delayed, rather than at admission. Some women might have declined participation in the study due to the difficulty of making a decision just before initiation of the treatment. Determining the optimal time to ask a women in labour if she wants to participate in a study could be regarded as an ethical dilemma. We decided not to ask all the nulliparous women, eligible at admission, in order to avoid involving women with normal labour progress in the study.
Interpretation of the findings
Our hypothesis was based on two systematic reviews 17, 18 that investigated the research field regarding augmentation of labour with a high-dose compared to a low-dose of oxytocin for reducing the incidence of CS. These reviews, based on small numbers of trials some of which were quasi-randomised, indicated with weak evidence that the use of high-dose oxytocin was associated with a lower frequency of CS. Our study, as well as the retrospective study by Zhang et al, 5 could not confirm their results. Maybe the differences in dose initiated and dose increases, or different levels of risk of bias and involvement of both nulliparous and multiparous women in the different trials included in the two systematic reviews, might explain our divergent results. It may also be that, in Sweden, a longer period of time in labour is permitted, compared with studies conducted in other countries with more stringent regulations, where women have a CS for "failure to progress" at a much earlier time.
It is known that a labour lasting too many hours can affect women's birth experiences negatively. [30] [31] [32] [33] Our results showed a modest reduction in the duration of labour (23 mins) in the highdose group compared with a 1.5 h reduction in the meta-analysis by Wei et al, 18 and 1.3 h in the retrospective study carried out by Zhang et al. 5 We found a great variation in length of labour in both groups.
The influence of oxytocin use on neonatal outcomes has been widely discussed. 15 The drug is not harmless and it can lead to hyperactive uterine contractions with negative outcomes for both mother and child. 12, 34 However, no harm has been observed when the drug is used in an appropriate way. 34 Adverse neonatal outcomes did not differ significantly between the two dosage groups despite the increased incidence of uterine tachysystole in the high-dose group and the longer labours in the low-dose group. This can be explained by the rigorous control in both groups based on the use of a checklist protocol. According to previous research, nulliparous women with a high body mass index (BMI) have an increased risk of CS due to delayed labour progress. [35] [36] [37] In our study, with a small group of women with obesity (BMI > 30), the interaction analysis of BMI or weight gain during pregnancy did not reveal any differences in CS rate between the two study regimens, although the study was not powered for this. The impact of oxytocin dose for augmentation of labour in relation to BMI thus needs to be further investigated.
Conclusion
We found no difference in CS rate between the high-oxytocin and low-oxytocin dose regimens for the treatment of delayed labour in nulliparous women in this study. Women in the high-dose group received a larger total amount of oxytocin and had a shorter duration of labour (by 23 min), and had more events of tachysystole compared to women in the low-dose group, without any impact on other maternal and neonatal outcomes. Both groups had similar rates of instrumental vaginal birth; in the high-dose group, the main indication was fetal distress and in the low dose group the main indication was failure to progress. We found no advantages for the routine use of high-dose of oxytocin in the management of delay in labour. Low-dose oxytocin regimen is to be recommended to avoid unnecessary events of tachysystole and fetal distress.
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